Lexaria Bioscience (LEXX) Assets Average (2012 - 2026)

Lexaria Bioscience has disclosed Assets Average across 15 years of filings, most recently posting $6.3 million for Q1 2026.

• Assets Average for Q1 2026 came in at $6.3 million, down 32.12% year-over-year; the trailing twelve-month figure through Feb 2026 was $6.3 million (down 32.12% YoY), and the FY2025 annual result was $6.5 million, up 9.13% from the prior year.
• Assets Average came in at $6.3 million for Q1 2026 at Lexaria Bioscience, up from $5.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $11.6 million in Q1 2022 to a low of $98100.0 in Q1 2024.
• The 5-year median for Assets Average is $5.5 million (2025), against an average of $5.7 million.
• Across the five-year window, Assets Average slumped 92.93% in 2023 and surged 9314.55% in 2025, its largest moves.
• Lexaria Bioscience's Assets Average stood at $4.0 million in 2022, then sank by 59.55% to $1.6 million in 2023, then jumped by 480.16% to $9.3 million in 2024, then slumped by 45.2% to $5.1 million in 2025, then advanced by 22.61% to $6.3 million in 2026.
• The last three Assets Average figures came in at $6.3 million (Q1 2026), $5.1 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.